Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Perphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.78 |
| ▸ | LMNA | P02545 | 8/20 | 0.78 |
| ▸ | MAPT | P10636 | 7/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.78 |
| ▸ | HRH1 | P35367 | 6/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.78 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.78 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.78 |
| ▸ | HTR2A | P28223 | 5/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.78 |
| ▸ | DRD3 | P35462 | 5/20 | 0.78 |
| ▸ | HTR2B | P41595 | 5/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.78 |
| ▸ | RAD52 | P43351 | 5/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.78 |
| ▸ | HTR1A | P08908 | 4/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perphenazine SCHEMBL3194369 | 0.96 | LMNA (0.75) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL144029 | 0.96 | LMNA (0.75) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL1069229 | 0.95 | LMNA (0.79) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL1071642 | 0.92 | LMNA (0.84) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL10394002 | 0.92 | LMNA (0.68) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL10394001 | 0.92 | LMNA (0.68) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL246992 | 0.91 | MAPT (0.78) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL28456705 | 0.90 | MAPT (0.88) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| SCHEMBL21525461 | 0.90 | MAPT (0.76) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL1069230 | 0.90 | MAPT (0.76) | LMNAMAPTMAPK1HRH1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108606-A1 | Conjugated psychotropic drugs and uses thereof | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2008-05-08 | — | — | US | claimed |
| EP-2275143-B1 | Conjugates of perphenazine or fluphenazine with carboxylic acids | UNIV RAMOT (IL) | 2012-12-19 | — | — | EP | disclosed |
| US-20120309748-A1 | CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF | BAR-ILAN UNIVERSITY (IL) | 2012-12-06 | — | — | US | disclosed |
| US-8283381-B2 | Conjugated psychotropic drugs and uses thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-10-09 | — | — | US | disclosed |
| US-8168628-B2 | Conjugated psychotropic drugs and uses thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-05-01 | — | — | US | disclosed |
| EP-1429844-B1 | CONJUGATE OF PERPHENAZINE AND GABA AND USES THEREOF | UNIV RAMOT (IL) | 2012-01-18 | — | — | EP | disclosed |
| US-7939525-B2 | Conjugated psychotropic drugs and uses thereof | BAR-ILAN UNIVERSITY (IL) | 2011-05-10 | — | — | US | disclosed |
| EP-2275143-A2 | Conjugated anti-psychotic drugs and uses thereof | Ramot at Tel Aviv University Ltd. (IL) | 2011-01-19 | — | — | EP | disclosed |
| US-20100204469-A1 | CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2010-08-12 | — | — | US | disclosed |
| US-20100120755-A1 | Conjugated psychotropic drugs and uses thereof | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2010-05-13 | — | — | US | disclosed |
| US-20080108606-A1 | Conjugated psychotropic drugs and uses thereof | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2008-05-08 | — | — | US | disclosed |
| US-20070197514-A1 | Conjugated psychotropic drugs and uses thereof | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2007-08-23 | — | — | US | disclosed |
| US-20070099977-A1 | Conjugated psychotropic drugs and uses thereof | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2007-05-03 | — | — | US | disclosed |
| EP-1727566-A2 | CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF | Ramot at Tel Aviv University Ltd. (IL) | 2006-12-06 | — | — | EP | disclosed |
| EP-1429844-A4 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | UNIV RAMOT (IL) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005092392-A2 | CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2005-10-06 | — | — | WO | disclosed |
| US-20040242570-A1 | Conjugated psychotropic drugs and uses thereof | BAR-ILAN UNIVERSITY (IL) | 2004-12-02 | — | — | US | disclosed |
| EP-1429844-A2 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | Ramot at Tel Aviv University Ltd. (IL) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003026563-A9 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | UNIV RAMOT (IL) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003026563-A2 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242570-A1 | Conjugated psychotropic drugs and uses thereof | SLC18A2, SLC6A3, SLCO1B3 | DRD2 32/4885LMNA 4629/4885MAPT 432/4885 |
| US-20070099977-A1 | Conjugated psychotropic drugs and uses thereof | SLC18A2, SLC6A3, SLCO1B3 | DRD2 32/4885LMNA 4629/4885MAPT 432/4885 |
| US-20100204469-A1 | CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF | SLC18A2, SLC6A3, SLCO1B3 | DRD2 32/4885LMNA 4629/4885MAPT 432/4885 |
| US-20100120755-A1 | Conjugated psychotropic drugs and uses thereof | SLC18A2, SLC6A3, SLCO1B3 | DRD2 32/4885LMNA 4629/4885MAPT 432/4885 |
| US-20080108606-A1 | Conjugated psychotropic drugs and uses thereof | SLC18A2, SLC6A3, SLCO1B3 | DRD2 32/4885LMNA 4629/4885MAPT 432/4885 |
| US-20070197514-A1 | Conjugated psychotropic drugs and uses thereof | SLC18A2, SLC6A3, SLCO1B3 | DRD2 32/4885LMNA 4629/4885MAPT 432/4885 |
| US-20120309748-A1 | CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF | SLC18A2, SLC6A3, SLCO1B3 | DRD2 32/4885LMNA 4629/4885MAPT 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.